A Multicenter, Open-label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination With Everolimus to Treat Subjects With Advanced Renal Cell Carcinoma

Trial Profile

A Multicenter, Open-label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination With Everolimus to Treat Subjects With Advanced Renal Cell Carcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 May 2017

At a glance

  • Drugs RX 0201 (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Rexahn Pharmaceuticals
  • Most Recent Events

    • 04 May 2017 According to a Rexahn Pharmaceuticals media release, the company anticipates to provide an update from the study later in the year 2017.
    • 07 Jun 2016 Interim results (n=10) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2016 Results published in Rexahn Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top